Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus

New England Journal of Medicine · 1993 · 24.7K citations · Full text

Medicine, Endocrinology, Internal Medicine +14

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Federica Sallusto, Danielle Lenig, Reinhold Förster et al. · Nature · 1999 · 5.8K citations

Life Sciences, Cell Biology, Immunology +14

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

Kevan C. Herold, William Hagopian, Julie Auger et al. · New England Journal of Medicine · 2002 · 1.2K citations · Full text

Life Sciences, Endocrinology, Immunology +14

Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes

Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text

Medicine, Endocrinology, Immunology +17

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

Life Sciences, Endocrinology, Immunology +16